The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Q. Is there any cure for psoriasis? A. There’s no cure for psoriasis yet, but there are many ways to get relief from the symptoms of this troublesome disease. Psoriasis is one of the most ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates ...

With approvals in rheumatoid arthritis, psoriasis, and Crohn's disease, Humira holds a wide range of indications, but biosimilar versions of the drug led to price erosion beginning in 2023 and ...

UnitedHealth to Remove AbbVie's Humira From Some US Drug Reimbursement ... differences in the risk for PsA among patients with psoriasis treated with interleukin (IL)-23 inhibitors and those ...

Humira is the company's blockbuster immunology ... It raised its combined outlook for psoriasis treatment Skyrizi and arthritis drug Rinvoq to more than $31 billion through 2027 and said it ...